Optimizing Prostate Cancer Management: Leveraging PSMA Imaging to Enhance Treatment Strategies : Episode 11
Evaluating the Role of Cu-PSMA PET Imaging in Prostate Cancer
Panelists discuss how, Copper-64 (^64Cu)–labeled PSMA-targeted PET imaging is emerging as a promising modality in prostate cancer diagnosis. The phase 2 SOLAR study (NCT05653856) demonstrated that ^64Cu-PSMA I&T PET/CT effectively detects metastatic prostate cancer, meeting primary end points related to correct localization rates. Compared with gallium-68 (^68Ga) and fluorine-18 (^18F), ^64Cu offers a half-life of approximately 12.7 hours, facilitating centralized production and distribution, which may improve accessibility
Video content above is prompted by the following:
- Discuss the emerging role of CU-PSMA-targeted PET imaging in prostate cancer.
- SOLAR phase 2 study – Cu-64-PSMA I&T (NCT05653856)
- 61Cu-PSMA–targeted PET for prostate cancer (Bernabeu et al. J Nucl Med. 2024)
- How do copper isotopes compare with others (gallium and fluorine) in terms of half-life, production logistics, image quality, etc?
- What potential advantages may copper-based isotopes offer over gallium or fluorine isotopes?
- Where do you see Cu-PSMA–targeted PET fitting in the current treatment landscape, and how might it influence future treatment approaches in prostate cancer?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
Related Content
